Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification.
Shimoda Igawa Y, Yoshida T, Makihara R, Torasawa M, Tateishi A, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Ohe Y.
Shimoda Igawa Y, et al. Among authors: goto y.
Lung Cancer. 2024 Sep 12;196:107954. doi: 10.1016/j.lungcan.2024.107954. Online ahead of print.
Lung Cancer. 2024.
PMID: 39303401